Alpha Therapeutic may continue distribution of albumin and IGIV reworked products under consent decree.
ALPHA THERAPEUTIC MAY CONTINUE DISTRIBUTION OF ALBUMIN AND IGIV PRODUCTS using reworked or rejected lots "only to the extent that such practices are explicitly provided for in valid product license applications held by Alpha and approved by CBER," states a consent decree signed by the company and FDA Jan. 27. Alpha must submit new validation data within six months to FDA. If the agency finds the data are insufficient it may request that the company stop distribution of the albumin (Albutein) and IGIV (Venoglobulin-S) products. The company says that it holds "valid product licenses for IGIV and Albumin which explicitly provide for these practices."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth